近期摄入直接口服抗凝药的缺血性卒中患者接受静脉溶栓治疗
这项国际多中心回顾性队列研究纳入832例近期摄入直接口服抗凝药(DOAC)的缺血性卒中患者与32375例对照,比较静脉溶栓后36小时内症状性颅内出血(sICH)风险。DOAC组sICH发生率为2.5%(95%CI 1.6-3.8),对照组为4.1%(95%CI 3.9-4.4),校正后OR为0.57(95%CI 0.36-0.92)。作者认为,在这项研究中,对于近期摄入DOAC的选定缺血性卒中患者,超说明书静脉溶栓与过度伤害相关的证据不足。
要点
- 近期摄入DOAC的卒中患者静脉溶栓后sICH率为2.5%(95%CI 1.6-3.8),低于无抗凝对照组的4.1%(95%CI 3.9-4.4)。
- 校正后分析显示近期DOAC摄入与静脉溶栓后sICH风险降低相关(校正OR 0.57,95%CI 0.36-0.92)。
- 该关联在不同选择策略及可检测血药浓度或极近期摄入的敏感性分析中保持一致。
核心结论
- 在这项研究中,对于近期摄入DOAC的选定缺血性卒中患者,超说明书静脉溶栓与过度伤害相关的证据不足。
研究设计与样本
- 国际多中心回顾性队列研究,纳入欧洲、亚洲、澳大利亚和新西兰64个初级和综合性卒中中心。
- 连续纳入接受静脉溶栓(伴或不伴取栓)的成年缺血性卒中患者,排除末次DOAC摄入距卒中发作超过48小时者。
- 832例近期使用DOAC的患者与32375例无近期DOAC使用的对照者进行比较,数据收集时间为2008年1月至2021年12月。
主要发现
- DOAC组sICH未校正发生率为2.5%(95%CI 1.6-3.8),无抗凝对照组为4.1%(95%CI 3.9-4.4)。
- 近期DOAC摄入与静脉溶栓后sICH风险降低相关(校正OR 0.57,95%CI 0.36-0.92)。
- 832例DOAC患者中,252例(30.3%)在溶栓前接受DOAC逆转治疗(均为依达赛珠单抗),225例(27.0%)进行了DOAC血药浓度检测,355例(42.7%)未检测血药浓度也未接受逆转治疗即行静脉溶栓。
- 该关联在不同选择策略及可检测血药浓度或极近期摄入的敏感性分析中保持一致。
关键数值与推荐
- sICH定义为静脉溶栓后36小时内美国国立卫生研究院卒中量表评分恶化至少4分,且归因于影像学证实的颅内出血。
- 近期DOAC摄入定义为静脉溶栓前48小时内确认末次摄入。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: International guidelines recommend avoiding intravenous thrombolysis (IVT) in patients with ischemic stroke who have a recent intake of a direct oral anticoagulant (DOAC). OBJECTIVE: To determine the risk of symptomatic intracranial hemorrhage (sICH) associated with use of IVT in patients with recent DOAC ingestion. DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter, retrospective cohort study included 64 primary and comprehensive stroke centers across Europe, Asia, Australia, and New Zealand. Consecutive adult patients with ischemic stroke who received IVT (both with and without thrombectomy) were included. Patients whose last known DOAC ingestion was more than 48 hours before stroke onset were excluded. A total of 832 patients with recent DOAC use were compared with 32 375 controls without recent DOAC use. Data were collected from January 2008 to December 2021. EXPOSURES: Prior DOAC therapy (confirmed last ingestion within 48 hours prior to IVT) compared with no prior oral anticoagulation. MAIN OUTCOMES AND MEASURES: The main outcome was sICH within 36 hours after IVT, defined as worsening of at least 4 points on the National Institutes of Health Stroke Scale and attributed to radiologically evident intracranial hemorrhage. Outcomes were compared according to different selection strategies (DOAC-level measurements, DOAC reversal treatment, IVT with neither DOAC-level measurement nor idarucizumab). The association of sICH with DOAC plasma levels and very recent ingestions was explored in sensitivity analyses. RESULTS: Of 33 207 included patients, 14 458 (43.5%) were female, and the median (IQR) age was 73 (62-80) years. The median (IQR) National Institutes of Health Stroke Scale score was 9 (5-16). Of the 832 patients taking DOAC, 252 (30.3%) received DOAC reversal before IVT (all idarucizumab), 225 (27.0%) had DOAC-level measurements, and 355 (42.7%) received IVT without measuring DOAC plasma levels or reversal treatment. The unadjusted rate of sICH was 2.5% (95% CI, 1.6-3.8) in patients taking DOACs compared with 4.1% (95% CI, 3.9-4.4) in control patients using no anticoagulants. Recent DOAC ingestion was associated with lower odds of sICH after IVT compared with no anticoagulation (adjusted odds ratio, 0.57; 95% CI, 0.36-0.92). This finding was consistent among the different selection strategies and in sensitivity analyses of patients with detectable plasma levels or very recent ingestion. CONCLUSIONS AND RELEVANCE: In this study, there was insufficient evidence of excess harm associated with off-label IVT in selected patients after ischemic stroke with recent DOAC ingestion.
引用
- Meinel TR, Wilson D, Gensicke H, et al. Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants. JAMA Neurol. 2023. PMID: 36807495. doi:10.1001/jamaneurol.2022.4782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。